线粒体抑制剂:乳腺癌治疗的新视野
Yalan Yan1, Sijie Li2, Lanqian Su1
1Clinical Medical College, Southwest Medical University, Luzhou, China.
Frontiers in pharmacology
|July 19, 2024
概括
准线粒体代谢提供了有前途的乳腺癌疗法. 将线粒体抑制剂与标准治疗相结合或向多个途径可以克服耐药性并提高疗效.
科学领域:
- 在瘤学瘤学.
- 细胞的新陈代谢
- 生物化学 生物化学
背景情况:
- 乳腺癌对健康构成重大挑战,原因是乳腺癌对标准治疗的耐药性.
- 代谢异质性和可塑性是乳腺癌的关键特征.
- 线粒体代谢越来越被认为是癌症进展的关键因素.
研究的目的:
- 审查线粒体代谢功能在乳腺癌中的作用.
- 概述线粒体功能障碍对乳腺癌亚型的影响.
- 讨论线粒体抑制剂作为潜在的治疗策略.
主要方法:
- 关于乳腺癌中线粒体代谢途径的文献综述.
- 分析不同乳腺癌亚型中的代谢重编程.
- 评估当前和潜在的线粒体抑制剂.
主要成果:
- 线粒体功能如OXPHOS和代谢途径在乳腺癌中至关重要.
- 线粒体功能障碍在乳腺癌亚型中不同影响代谢途径.
- 向线粒体抑制剂显示出单一治疗或辅助治疗的潜力.
结论:
- 线粒体代谢是乳腺癌治疗的可行目标.
- 克服挑战需要结合疗法或针对多个代谢途径.
- 进一步开发线粒体抑制剂可能会提高乳腺癌治疗效率.
更多相关视频
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
18.7K
07:12Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor
Published on: October 26, 2017
7.8K
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Electron Transport Chain: Complex I and II
12.7K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.7K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
